Tvardi Therapeutics: 'Sell' Rating On IPF Drug TTI-101 Advancement Uncertainty

With only $41 million in cash, Tvardi Therapeutics may need to raise additional funds within a one-year period. Click here to ...
Slate

The Solution to America’s Housing Crisis Might Be Built in a Factory

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. On a quiet street 2 miles north of Boston ...

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Ann…

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be ...